Uterine sarcoma

Jump to navigation Jump to search

WikiDoc Resources for Uterine sarcoma

Articles

Most recent articles on Uterine sarcoma

Most cited articles on Uterine sarcoma

Review articles on Uterine sarcoma

Articles on Uterine sarcoma in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Uterine sarcoma

Images of Uterine sarcoma

Photos of Uterine sarcoma

Podcasts & MP3s on Uterine sarcoma

Videos on Uterine sarcoma

Evidence Based Medicine

Cochrane Collaboration on Uterine sarcoma

Bandolier on Uterine sarcoma

TRIP on Uterine sarcoma

Clinical Trials

Ongoing Trials on Uterine sarcoma at Clinical Trials.gov

Trial results on Uterine sarcoma

Clinical Trials on Uterine sarcoma at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Uterine sarcoma

NICE Guidance on Uterine sarcoma

NHS PRODIGY Guidance

FDA on Uterine sarcoma

CDC on Uterine sarcoma

Books

Books on Uterine sarcoma

News

Uterine sarcoma in the news

Be alerted to news on Uterine sarcoma

News trends on Uterine sarcoma

Commentary

Blogs on Uterine sarcoma

Definitions

Definitions of Uterine sarcoma

Patient Resources / Community

Patient resources on Uterine sarcoma

Discussion groups on Uterine sarcoma

Patient Handouts on Uterine sarcoma

Directions to Hospitals Treating Uterine sarcoma

Risk calculators and risk factors for Uterine sarcoma

Healthcare Provider Resources

Symptoms of Uterine sarcoma

Causes & Risk Factors for Uterine sarcoma

Diagnostic studies for Uterine sarcoma

Treatment of Uterine sarcoma

Continuing Medical Education (CME)

CME Programs on Uterine sarcoma

International

Uterine sarcoma en Espanol

Uterine sarcoma en Francais

Business

Uterine sarcoma in the Marketplace

Patents on Uterine sarcoma

Experimental / Informatics

List of terms related to Uterine sarcoma

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [2]Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [3]

Overview

A uterine sarcoma is a malignant tumor that arises from the smooth muscle or connective tissue of the uterus. If the lesion originates from the stroma of the uterine lining it is an endometrial stromal sarcoma, and if the uterine muscle cell is the originator, the tumor is a uterine leiomyosarcoma. A lesion that also contains malignant tumor cells of epithelial origin is termed uterine carcinosarcoma (formerly called malignant mixed mesodermal/mullerian tumor).

Classification

Cellular Classification of Uterine Sarcoma.[1]
The most common histologic types of uterine sarcomas include:
  • Carcinosarcomas (mixed mesodermal sarcomas [40%–50%]).
  • Leiomyosarcomas (30%).
  • Endometrial stromal sarcomas (15%).

Histology

Tumoral entities include leiomyosarcomas, endometrial stromal sarcomas, carcinosarcomas and "other" sarcomas.[2]

  • If the lesion originates from the stroma of the uterine lining it is an endometrial stromal sarcoma.
  • If the uterine muscle cell is the originator the tumor is a uterine leiomyosarcoma.
  • Carcinosarcomas comprise both malignant epithelial and malignant sarcomatous components.

Epidemiology

The vast majority of malignancies of the uterine body are endometrial carcinomas - only about 4% will be uterine sarcomas.[3]

Risk Factors

  • The only documented etiologic factor in 10% to 25% of these malignancies is prior pelvic radiation therapy, which is often administered for benign uterine bleeding that began 5 to 25 years earlier.
  • An increased incidence of uterine sarcoma has been associated with tamoxifen in the treatment of breast cancer.[4]

Signs and Symptoms

  • Unusual or postmenopausal bleeding may be a sign of a malignancy including uterine sarcoma and needs to be investigated
  • Pelvic pain
  • Pelvic pressure
  • Unusual vaginal discharge

Diagnosis

Investigations by the physician include imaging (ultrasound, CAT scan, MRI) and, if possible, obtaining a tissue diagnosis by biopsy, hysteroscopy, or D&C. Ultimately the diagnosis is established by the histologic examination of the specimen. Typically malignant lesions have >10 mitosis per high power field. In contrast a uterine leiomyoma as a benign lesion would have < 5 mitosis per high power field.

Staging

Uterine sarcoma is staged using the FIGO cancer staging system.[5]

  • Stage I: tumor confined to the corpus uteri
  • Stage IA: no or less than half myometrial invasion
  • Stage IB: invasion equal to or more than half of the myometrium
  • Stage II : tumor invades cervical stroma but does not extend beyond the uterus
  • Stage III: local and/or regional spread of the tumor
  • Stage IIIA: tumor invades the serosa of the corpus uteri and/or adnexae
  • Stage IIIB: vaginal involvement and/or parametrial involvement
  • Stage IIIC: metastases to pelvic and/or para-aortic lymph nodes
  • Stage IIIC1: positive pelvic nodes
  • Stage IIIC2: positive para-aortic nodes with or without positive pelvic lymph nodes
  • Stage IV: tumor invades bladder and/or bowel mucosa, and/or distant metastases
  • Stage IVA: tumor invasion of bladder and/or bowel mucosa
  • Stage IVB: distant metastasis, including intra-abdominal metastases and/or inguinal nodes

Therapy

Surgery is often the principal means of diagnosis and is the primary treatment for all patients with uterine sarcoma. If the diagnosis is known, the extent of surgery is planned according to the stage of the tumor.

Stage I Uterine Sarcoma

  • Standard treatment options:

Stage II Uterine Sarcoma

  • Standard treatment options:
  • Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and periaortic selective lymphadenectomy)
  • Surgery plus pelvic radiation therapy
  • Surgery plus adjuvant chemotherapy

Stage III Uterine Sarcoma

  • Standard treatment options:
  • Surgery (total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic and periaortic selective lymphadenectomy, and resection of all gross tumor)
  • Treatment options under clinical evaluation:
  • Surgery plus pelvic radiation therapy
  • Surgery plus adjuvant chemotherapy

Stage IV Uterine Sarcoma

See also

References

  1. "uterine sarcoma".
  2. Zagouri F, Dimopoulos AM, Fotiou S, Kouloulias V, Papadimitriou CA (2009). "Treatment of early uterine sarcomas: disentangling adjuvant modalities". World J Surg Oncol. 7: 38. doi:10.1186/1477-7819-7-38. PMC 2674046. PMID 19356236.
  3. [1] American Cancer Society information, accessed 03-11-2006
  4. "uterine sarcoma".
  5. "uterine sarcoma staging".

External links

Template:WikiDoc Sources